CVE:IGX

IntelGenx Technologies Competitors

C$0.55
+0.01 (+1.85 %)
(As of 04/20/2021 11:26 AM ET)
Add
Compare
Today's Range
C$0.55
Now: C$0.55
C$0.59
50-Day Range
C$0.35
MA: C$0.50
C$0.66
52-Week Range
C$0.17
Now: C$0.55
C$0.67
Volume74,142 shs
Average Volume63,161 shs
Market CapitalizationC$61.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

IntelGenx Technologies (CVE:IGX) Vs. IPA, HBP, ACST, NVH, MBX, and PDP

Should you be buying IGX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to IntelGenx Technologies, including ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), Acasti Pharma (ACST), Novoheart (NVH), Microbix Biosystems (MBX), and Pediapharm (PDP).

IntelGenx Technologies (CVE:IGX) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares IntelGenx Technologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for IntelGenx Technologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
ImmunoPrecise Antibodies0000N/A

Earnings & Valuation

This table compares IntelGenx Technologies and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79
ImmunoPrecise AntibodiesC$17.18 million13.08C$-4,082,906.00C($0.21)-55.05

ImmunoPrecise Antibodies has higher revenue and earnings than IntelGenx Technologies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

IntelGenx Technologies beats ImmunoPrecise Antibodies on 3 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares IntelGenx Technologies and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
Helix BioPharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for IntelGenx Technologies and Helix BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Helix BioPharma0000N/A

Valuation & Earnings

This table compares IntelGenx Technologies and Helix BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79
Helix BioPharmaN/AN/AN/AC($0.06)-16.00

Helix BioPharma has lower revenue, but higher earnings than IntelGenx Technologies. Helix BioPharma is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

IntelGenx Technologies beats Helix BioPharma on 2 of the 3 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Acasti Pharma (CVE:ACST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for IntelGenx Technologies and Acasti Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Acasti Pharma0000N/A

Profitability

This table compares IntelGenx Technologies and Acasti Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
Acasti PharmaN/AN/AN/A

Valuation & Earnings

This table compares IntelGenx Technologies and Acasti Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79
Acasti PharmaC$81,000.001,334.13C$6.80 millionC$0.0315.88

Acasti Pharma has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Acasti Pharma beats IntelGenx Technologies on 4 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Profitability

This table compares IntelGenx Technologies and Novoheart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
NovoheartN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for IntelGenx Technologies and Novoheart, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Novoheart0000N/A

Valuation and Earnings

This table compares IntelGenx Technologies and Novoheart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95

Novoheart has lower revenue, but higher earnings than IntelGenx Technologies. Novoheart is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Novoheart beats IntelGenx Technologies on 3 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares IntelGenx Technologies and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Valuation and Earnings

This table compares IntelGenx Technologies and Microbix Biosystems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79
Microbix BiosystemsC$11.64 million5.55C$-5,581,797.00C($0.05)-11.57

Microbix Biosystems has higher revenue and earnings than IntelGenx Technologies. Microbix Biosystems is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for IntelGenx Technologies and Microbix Biosystems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Microbix Biosystems0000N/A

Summary

Microbix Biosystems beats IntelGenx Technologies on 3 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares IntelGenx Technologies and Pediapharm's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11

IntelGenx Technologies has higher earnings, but lower revenue than Pediapharm. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IntelGenx Technologies and Pediapharm, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Pediapharm0000N/A

Profitability

This table compares IntelGenx Technologies and Pediapharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
PediapharmN/AN/AN/A

Summary

Pediapharm beats IntelGenx Technologies on 3 of the 5 factors compared between the two stocks.


IntelGenx Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IPA
ImmunoPrecise Antibodies
0.4$11.78+3.7%C$123.03 millionC$17.18 million-55.05
HBP
Helix BioPharma
0.5$0.88+2.3%C$119.96 millionN/A-16.00Gap Up
ACST
Acasti Pharma
0.8$0.54+1.9%C$88.79 millionC$81,000.0015.88News Coverage
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.59+3.4%C$66.76 millionC$11.64 million-11.57News Coverage
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.39+11.5%C$58.80 millionC$123,870.00-30.00
PMN
ProMIS Neurosciences
0.5$0.19+2.7%C$55.07 millionC$1,787.00-9.25News Coverage
Gap Up
COV
Covalon Technologies
0.6$1.55+3.2%C$37.44 millionC$23.84 million-6.51Gap Down
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36Gap Up
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+1.4%C$21.65 millionC$16.14 million22.42
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20+2.6%C$14.12 millionC$1.34 million-5.57
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42High Trading Volume
PAS
Pascal Biosciences
0.6$0.08+0.0%C$12.70 millionN/A-3.64
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.34+1.5%C$10.16 millionC$4.12 million30.45Gap Down
HEM
Hemostemix
0.6$0.33+6.2%C$9.07 millionN/A-1.93Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.61+5.8%C$4.48 millionN/A-1.17
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.92+1.4%C$0.00C$267.59 million51.56
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.